Biotech · Private company
Telix Pharmaceuticals (Innovations) Pty Limited
Track this companyFree. Adds Telix Pharmaceuticals (Innovations) Pty Limited to your Dealase workspace and tells you when its record changes.
Clinical trials1811 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline13
- 177Lu-TLX591Phase 3 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- 68Ga-PSMA-11Phase 3 · PCAClinicalTrials.gov · fetched Nov 12, 2026
- 89Zr-girentuximabPhase 3 · Clear Cell Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- AbirateronePhase 3 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 3 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- EnzalutamidePhase 3 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- 177Lu-TLX250Phase 2 · ccRCCClinicalTrials.gov · fetched Nov 12, 2026
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumorsPhase 2 · Cervical CancerClinicalTrials.gov · fetched Nov 12, 2026
- 153Sm-DOTMPPhase 1 · Bone PainClinicalTrials.gov · fetched Nov 12, 2026
- 18F-FloretyrosineGlioma (Any Grade) in the BrainClinicalTrials.gov · fetched Nov 12, 2026
- 18F(FET)PETRetrospective StudyClinicalTrials.gov · fetched Nov 12, 2026
- 89Zr-DFO-girentuximabClear Cell Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- None- ObservationalProstate Cancer (Adenocarcinoma)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials18
- Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCCPHASE2 · NOT_YET_RECRUITING · started Oct 15, 2026ClinicalTrials.gov NCT07870746 · fetched Nov 12, 2026
- Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy DeliveryEARLY_PHASE1 · NOT_YET_RECRUITING · started Oct 1, 2026ClinicalTrials.gov NCT07674771 · fetched Nov 12, 2026
- CAIX PET/CT for Residual or Recurrent Post-ablative ccRCCPHASE2 · NOT_YET_RECRUITING · started Sep 16, 2026ClinicalTrials.gov NCT07077083 · fetched Nov 12, 2026
- Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone PainPHASE1 · RECRUITING · started Oct 21, 2025ClinicalTrials.gov NCT07197645 · fetched Nov 12, 2026
- [18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related ChangesCOMPLETED · started Sep 22, 2025ClinicalTrials.gov NCT07238322 · fetched Nov 12, 2026
- PSMA PET Combined With MRI for the Detection of PCaPHASE3 · ACTIVE_NOT_RECRUITING · started Aug 18, 2025ClinicalTrials.gov NCT07052214 · fetched Nov 12, 2026
- Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging EvaluationsTERMINATED · started Jan 30, 2025ClinicalTrials.gov NCT06655064 · fetched Nov 12, 2026
- An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney CancerPHASE2 · RECRUITING · started Aug 6, 2024ClinicalTrials.gov NCT06447103 · fetched Nov 12, 2026
- The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)PHASE3 · RECRUITING · started Jul 26, 2024ClinicalTrials.gov NCT06520345 · fetched Nov 12, 2026
- PSMA PET Response Guided SabR in High Risk PcaPHASE1 · RECRUITING · started Mar 7, 2024ClinicalTrials.gov NCT06044857 · fetched Nov 12, 2026
- Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCPHASE1_PHASE2 · RECRUITING · started Jun 30, 2023ClinicalTrials.gov NCT05663710 · fetched Nov 12, 2026
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid TumorsPHASE2 · TERMINATED · started Jun 6, 2023ClinicalTrials.gov NCT05563272 · fetched Nov 12, 2026
- Total Body PET-CT Imaging of Prostate Cancer Using IlluccixEARLY_PHASE1 · UNKNOWN · started Nov 1, 2022ClinicalTrials.gov NCT05558956 · fetched Nov 12, 2026
- Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate CancerPHASE2 · RECRUITING · started Jun 30, 2020ClinicalTrials.gov NCT04402151 · fetched Nov 12, 2026
- 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON StudyPHASE3 · COMPLETED · started Aug 15, 2019ClinicalTrials.gov NCT03849118 · fetched Nov 12, 2026
- Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer OutcomesPHASE2 · ACTIVE_NOT_RECRUITING · started May 10, 2019ClinicalTrials.gov NCT03762759 · fetched Nov 12, 2026
- 89Zr-DFO-girentuximab Expanded Access Program (EAP)NO_LONGER_AVAILABLEClinicalTrials.gov NCT06090331 · fetched Nov 12, 2026
- 18F-Floretyrosine Expanded Access ProgramNO_LONGER_AVAILABLEClinicalTrials.gov NCT06743100 · fetched Nov 12, 2026